Phaseline

Companies › Scarcell Therapeutics S.A.S.

Scarcell Therapeutics S.A.S.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
allogeneic engineered Gingival Fibroblasts (aeGF)
cell therapy with anti-inflammatory effects and cartilage regeneration
–Phase 1Osteoarthritis, KneeFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06690710allogeneic engineered Gingival Fibroblasts (aeGF)Phase 1Osteoarthritis, KneeImmunologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.